RUBRA MEDICAMENTS LTD. - 531099 - Appointment of Company Secretary and Compliance Officer
Resignation and Appointment of Company Secretary and Compliance Officer07-12-2022
RUBRA MEDICAMENTS LTD. - 531099 - Appointment of Company Secretary and Compliance Officer
Resignation and Appointment of Company Secretary and Compliance OfficerRUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of unaudited Financial Results for the quarter and half year ended September 30, 2022RUBRA MEDICAMENTS LTD. - 531099 - Revised Outcome Of Board Meeting
1. This is to inform you that, the Board of Directors of the Company at its meeting held on Thursday, November 10, 2022 inter alia, has considered and approved the following: A. Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the half year ended September 30, 2022. B. Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015 for the half year ended September 30, 2022 The time of commencement of the Board Meeting was 03.00 PM and the time of conclusion was 3.30 PMRUBRA MEDICAMENTS LTD. - 531099 - Related Party Transaction For The Half Year Ended September 30, 2022
As per Regulation 23(9) of SEBI (LODR) Regulations, 2015, please find attached herewith disclosures of related party transactions for the half year ended September 30, 2022.RUBRA MEDICAMENTS LTD. - 531099 - Outcome Of Board Meeting
Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the half year ended September 30, 2022.RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Notice Of Board Meeting
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 ,inter alia, to consider and approve Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the half year ended September 30, 2022.RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Managing Director / Whole Time DirectorRUBRA MEDICAMENTS LTD. - 531099 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s ReportRUBRA MEDICAMENTS LTD. - 531099 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Voting results of 31st Annual General Meeting held on September 30, 2022RUBRA MEDICAMENTS LTD. - 531099 - Closure of Trading Window
Pursuant to the Company''s Securities Dealing Code, the Trading Window for dealing in the Company''s Equity Shares will remain closed from Saturday, October 1, 2022 for all Designated Employees of the Company. The closure is in connection with the declaration of unaudited financial results of the Company for the quarter ending September 30, 2022. The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchanges.